MINNEAPOLIS, Jan. 8, 2025
/PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today
announced it will showcase its new ProPak™ GMP cytokines, alongside
its portfolio of innovative products and solutions supporting cell
and gene therapy development and manufacturing at Phacilitate's
Advanced Therapies Week, taking place January 20-23 at the Kay Bailey Hutchison
Convention Center in Dallas,
Texas.
Bio-Techne will feature its cell and gene therapy workflow
reproducibility and scalability solutions, including its portfolio
of high-quality reagents and analytical technologies, at booth 517.
Highlights include the recently launched ProPak liquid GMP
cytokines, which combine with Wilson
Wolf's G-Rex® bioreactor, available through ScaleReady, or
similar platforms to enable a closed process solution to streamline
and de-risk cytokine delivery for T cell manufacturing. The booth
will also showcase the Ella™ automated ELISA platform and its
Simple Plex™ assays, which represent the ideal solution for QC
release testing, as well as Bio-Techne's full suite of protein
analytical instruments for in-process and final product
characterization of cell and gene therapies.
Dr. David Hermanson, Principal
Scientist for Cell & Gene Therapy Research & Development at
Bio-Techne, will present a breakout session on closed system
manufacturing. The discussion will focus on strategies to ensure
flexibility and scalability throughout all phases of cell therapy
programs. He will also address critical regulatory, economic, and
quality control factors to consider when selecting cell therapy
manufacturing platforms. Dr. Hermanson's presentation will take
place on Tuesday, January 21 at
12:15 PM.
Dr. Hermanson will also host a product demonstration in the
Innovation Zone on Wednesday, January
22 at 10:00 AM, highlighting
the integration of ProPak cytokines into T cell manufacturing
workflows utilizing G-Rex bioreactors and the advantages of
adopting closed system solutions. Both ProPak GMP cytokines
and G-Rex bioreactors are available through Bio-Techne's strategic
partnership with ScaleReady.
"Bio-Techne is deeply committed to the highly efficient
manufacturing of lifesaving cell and gene-modified cell therapies,"
said Will Geist, President of
Bio-Techne's Protein Sciences Segment. "ProPak GMP Cytokines
provide the precise quantity of cytokines needed for highly
simplified closed system expansion of CAR-T and TCR-T cell drug
products with excellent cell characteristics. In addition to
ProPaks, we are looking forward to showcasing our full suite of
cell and gene therapy workflow solutions at this important
conference."
Breakout Presentation:
Closed Systems, Open Possibilities: Considerations for
Futureproofing Cell Therapy Manufacturing
Track: Cell
Therapy Manufacturing
Session: Considering the End Early – What Parts of the Process Can
You Get Right From the Start
Tuesday, January 21 at 12:15 PM, Theatre 1
Presenter: David Hermanson,
Ph.D.
Innovation Zone Product Demonstration:
Streamlining Cytokine Delivery for Scalable, Closed System T
Cell Manufacturing
Wednesday, January
22 at 10:00 AM, Innovation
Zone
Presenter: David Hermanson,
Ph.D.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences
company providing innovative tools and bioactive reagents for the
research and clinical diagnostic communities. Bio-Techne products
assist scientific investigations into biological processes and the
nature and progress of specific diseases. They aid in drug
discovery efforts and provide the means for accurate clinical tests
and diagnoses. With hundreds of thousands of products in its
portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has
approximately 3,100 employees worldwide. For more information on
Bio-Techne and its brands, please visit
http://www.bio-techne.com or follow the Company on social
media at Facebook, LinkedIn, Twitter or YouTube.
About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Vice
President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
About ScaleReady
ScaleReady provides the field of cell
and gene-modified cell therapy (CGT) with a G-Rex centric
manufacturing platform that enables the world's most practical,
flexible, scalable, and affordable CGT drug product development and
manufacturing.
The G-Rex manufacturing platform is currently used by a rapidly
growing list of over 800 organizations and is producing drug
products for approximately 50% of CGT clinical trials as well as 5
commercially approved CGT drugs.
CGT entities relying on the breadth and scope of ScaleReady's
expertise can expect to save years of time and millions of dollars
on the path to CGT commercialization.
For more information about the ScaleReady G-Rex® Grant Program,
please contact info@scaleready.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bio-techne-to-present-at-phacilitate-advanced-therapies-week-2025-302345274.html
SOURCE Bio-Techne Corporation
